In Vitro Activity of Ceftazidime-Avibactam against Isolates in a Phase 3 Open-Label Clinical Trial for Complicated Intra-Abdominal and Urinary Tract Infections Caused by Ceftazidime-Nonsusceptible Gram-Negative Pathogens

被引：23
|
作者：
Stone, Gregory G. [1 ]
Bradford, Patricia A. [1 ]
Newell, Paul [2 ]
Wardman, Angela [2 ]
机构：
[1] AstraZeneca, Waltham, MA 02451 USA
[2] AstraZeneca, Alderley Pk, England
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2017年 / 61卷 / 02期
关键词：
ceftazidime nonsusceptible; ceftazidime-avibactam; in vitro activity; BETA-LACTAMASE INHIBITOR; COMBINATION; NXL104;
D O I：
10.1128/AAC.01820-16
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
The in vitro activity of ceftazidime-avibactam was evaluated against 341 Gram-negative isolates from 333 patients in a randomized, phase 3 clinical trial of patients with complicated urinary tract or intra-abdominal infections caused by ceftazidime-nonsusceptible pathogens (NCT01644643). Ceftazidime-avibactam MIC90 values against Enterobacteriaceae and Pseudomonas aeruginosa (including several class B or D enzyme producers that avibactam does not inhibit) were 1 and 64 mu g/ml, respectively. Overall, the ceftazidime-avibactam activity against ceftazidime-nonsusceptible isolates was comparable to the activity of ceftazidime-avibactam previously reported against ceftazidime-susceptible isolates.
引用
收藏
页数：6
相关论文
共 35 条
  • [21] Clinical and Microbiological Outcomes of Ceftazidime-Avibactam Treatment in Adults with Gram-Negative Bacteremia: A Subset Analysis from the Phase 3 Clinical Trial Program
    John E. Mazuski
    Florian Wagenlehner
    Antoni Torres
    Yehuda Carmeli
    Joseph W. Chow
    Dalia Wajsbrot
    Gregory G. Stone
    Paurus Irani
    David Bharucha
    Karen Cheng
    Margaret Tawadrous
    Infectious Diseases and Therapy, 2021, 10 : 2399 - 2414
  • [22] β-Lactamase Characterization of Gram-Negative Pathogens Recovered from Patients Enrolled in the Phase 2 Trials for Ceftazidime-Avibactam: Clinical Efficacies Analyzed against Subsets of Molecularly Characterized Isolates
    Mendes, Rodrigo E.
    Castanheira, Mariana
    Gasink, Leanne
    Stone, Gregory G.
    Nichols, Wright W.
    Flamm, Robert K.
    Jones, Ronald N.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (03) : 1328 - 1335
  • [23] In vitro activity of ceftazidime-avibactam against gram-negative bacteria in patients with bacteremia and skin and soft-tissue infections in Colombia 2019-2021
    Lemos-Luengas, Elkin Vladimir
    Renteria-Valoyes, Sixta
    Munoz, Diana Marcela Almario
    Gonzalez, Cinthya Katherine Galindo
    Guerron-Gomez, Gabriela
    Ramos-Castaneda, Jorge Andres
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2024, 109 (02)
  • [24] Antimicrobial Activities of Ceftazidime-Avibactam and Comparator Agents against Gram-Negative Organisms Isolated from Patients with Urinary Tract Infections in US Medical Centers, 2012 to 2014
    Sader, Helio S.
    Castanheira, Mariana
    Flamm, Robert K.
    Jones, Ronald N.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (07) : 4355 - 4360
  • [25] In vitro activity of ceftazidime-avibactam and comparators against Gram-negative bacterial isolates collected in the Asia-Pacific region as part of the INFORM program (2015-2017)
    Ko, Wen-Chien
    Stone, Gregory G.
    ANNALS OF CLINICAL MICROBIOLOGY AND ANTIMICROBIALS, 2020, 19 (01)
  • [26] Aztreonam-avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial
    Carmeli, Yehuda
    Cisneros, Jose Miguel
    Paul, Mical
    Daikos, George L.
    Wang, Minggui
    Torre-Cisneros, Julian
    Singer, George
    Titov, Ivan
    Gumenchuk, Illia
    Zhao, Yongjie
    Jimenez-Rodriguez, Rosa-Maria
    Liang, Lu
    Chen, Gang
    Pyptiuk, Oleksandr
    Aksoy, Firdevs
    Rogers, Halley
    Wible, Michele
    Arhin, Francis F.
    Luckey, Alison
    Leaney, Joanne L.
    Pypstra, Rienk
    Chow, Joseph W.
    COMBACTE-CARE Consortium REVISIT Study Grp
    LANCET INFECTIOUS DISEASES, 2025, 25 (02): : 218 - 230
  • [27] In Vitro Activity of Ceftazidime-Avibactam against Isolates from Respiratory and Blood Specimens from Patients with Nosocomial Pneumonia, Including Ventilator-Associated Pneumonia, in a Phase 3 Clinical Trial
    Stone, Gregory G.
    Bradford, Patricia A.
    Tawadrous, Margaret
    Taylor, Dianna
    Cadatal, Mary Jane
    Chen, Zhangjing
    Chow, Joseph W.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (05)
  • [28] Safety and Efficacy of Ceftazidime-Avibactam Plus Metronidazole in the Treatment of Children ≥3 Months to <18 Years With Complicated Intra-Abdominal Infection: Results From a Phase 2, Randomized, Controlled Trial
    Bradley, John S.
    Broadhurst, Helen
    Cheng, Karen
    Mendez, Maria
    Newell, Paul
    Prchlik, Martin
    Stone, Gregory G.
    Talley, Angela K.
    Tawadrous, Margaret
    Wajsbrot, Dalia
    Yates, Katrina
    Zuzova, Antonina
    Gardner, Annie
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2019, 38 (08) : 816 - 824
  • [29] BUDGET IMPACT OF INTRODUCING CEFTAZIDIME-AVIBACTAM (CAZ-AVI) FOR COMPLICATED INTRA-ABDOMINAL INFECTION (CIAI), COMPLICATED URINARY TRACT INFECTIONS (CUTI), AND HOSPITAL ACQUIRED PNEUMONIA INCLUDING VENTILATOR-ASSOCIATED PNEUMONIA (HAPNAP) TO A HOSPITAL FORMULARY IN ITALY
    KongnakornT
    Tichy, E.
    Merinopoulou, E.
    Berto, M.
    Di Virgilio, R.
    Charbonneau, C.
    VALUE IN HEALTH, 2017, 20 (09) : A782 - A782
  • [30] In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections
    Bradford, PA
    Weaver-Sands, DT
    Petersen, PJ
    CLINICAL INFECTIOUS DISEASES, 2005, 41 : S315 - S332
1234